Literature DB >> 10636448

Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women.

J J Kastelein1, J M Ordovas, M E Wittekoek, S N Pimstone, W F Wilson, S E Gagné, M G Larson, E J Schaefer, J M Boer, C Gerdes, M R Hayden.   

Abstract

We assessed the effect of two common mutations in the lipoprotein lipase gene (LPL), D9N and N291S, which have been shown to modulate plasma lipids in a wide spectrum of patients. A total of 1114 men and 1 144 women from the Framingham Offspring Study (FOS) were analyzed for these two LPL variants. Subsequently, the association with fasting plasma lipids and risk of coronary artery disease (CHD) was determined. We extended our study by calculating weighed means of lipids and lipoproteins in carriers and non-carriers for these LPL mutations in patients with genetic dyslipidemias, CHD patients and healthy controls. In the FOS sample, the D9N and N291S alleles were associated with lower high-density lipoprotein-cholesterol (HDL-C) (delta = - 0.07 mmol/ 1, p = 0.03) and a trend towards increased triglycerides (delta = 0.25 mmol/ 1, p = 0.07). In women, a trend towards the high triglyceride, low HDL-C phenotype was evident (delta = - 0.02 mmol/1 for HDL-C and delta = 0.14 mmol/l for triglycerides, respectively). Cumulative analysis of other studies of male carriers of the D9N and N291S revealed higher levels of triglycerides (D291N; 2.60(1.85) mmol/l vs. 1.62(1.18) mmol/l: p < 0.0001) (D9N; 1.94 (1.19) mmol/l vs. 1.74(1.17) mmol/l: p < 0.001) and lower HDL-C (N291S; 1.04(0.32) mmol/l vs. 1.15(0.28) mmol/l: p < 0.0001) (D9N; 1.08(0.24) mmol/l vs. 1.16(0.28) mmol/l: p < 0.0001). In females, results differed with higher TG levels (N291S; 1.70(0.99) mmol/l vs. 1.10(0.63) mmol/l: p < 0.001) (D9N; 1.08(0.76) mmol/l vs. 0.96(0.51) mmol/l: p < 0.01) and lower HDL-C levels (N291S; 1.27(0.33) mmol/l vs. 1.51(0.32) mmol/l: p < 0.0001); however, the HDL-C levels for D9N carriers were similar to non-carriers (D9N; 1.52(0.29) mmol/l vs. 1.53(0.35) mmol/l: p = 0.83). Our data provide evidence that common variants of the LPL gene are significant modulators of lipid and lipoprotein levels in both men and women.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10636448     DOI: 10.1034/j.1399-0004.1999.560407.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

1.  Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Authors:  Arman Qamar; Sumeet A Khetarpal; Amit V Khera; Atif Qasim; Daniel J Rader; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-11       Impact factor: 8.311

2.  Genetic variants at the APOE, lipoprotein lipase (LpL), cholesteryl ester transfer protein (CETP), and endothelial nitric oxide (eNOS) genes and coronary artery disease (CAD): CETP Taq1 B2B2 associates with lower risk of CAD in Asian Indians.

Authors:  Aparna Amarendra Bhanushali; Bibhu R Das
Journal:  J Community Genet       Date:  2010-03-25

3.  Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein e knockout mice but not in C57BL/6 mice.

Authors:  K Wilson; G L Fry; D A Chappell; C D Sigmund; J D Medh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-11       Impact factor: 8.311

Review 4.  Genetic determinants of plasma triglycerides: impact of rare and common mutations.

Authors:  P J Talmud
Journal:  Curr Atheroscler Rep       Date:  2001-05       Impact factor: 5.113

5.  Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study.

Authors:  Kelly Volcik; Christie M Ballantyne; Henry J Pownall; A Richey Sharrett; Eric Boerwinkle
Journal:  J Stud Alcohol Drugs       Date:  2007-07       Impact factor: 2.582

6.  Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women.

Authors:  Stefania Lamon-Fava; Bela F Asztalos; Timothy D Howard; David M Reboussin; Katalin V Horvath; Ernst J Schaefer; David M Herrington
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-29       Impact factor: 3.478

7.  Equivalent binding of wild-type lipoprotein lipase (LPL) and S447X-LPL to GPIHBP1, the endothelial cell LPL transporter.

Authors:  Kirsten Turlo; Calvin S Leung; Jane J Seo; Chris N Goulbourne; Oludotun Adeyo; Peter Gin; Constance Voss; André Bensadoun; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  Biochim Biophys Acta       Date:  2014-04-02

8.  Association of Metabolic Syndrome with Aerobic Exercise and LPL rs3779788 Polymorphism in Taiwan Biobank Individuals.

Authors:  Chun-Sheng Hsu; Shin-Tsu Chang; Oswald Ndi Nfor; Kuan-Jung Lee; Chien-Chang Ho; Chuan-Ching Liu; Shiuan-Shinn Lee; Yung-Po Liaw
Journal:  Diabetes Metab Syndr Obes       Date:  2021-09-14       Impact factor: 3.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.